All Biologics articles – Page 2
-
NewsSamsung invests in Phrontline to advance next-gen ADC therapies
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
ArticleFast-tracking advanced therapies without compromising regulatory success
Early planning for potency CQAs, comparability and evolving global regulations can set advanced therapies on the fastest path to approval. Dr Christian Schneider shares how to prepare from the start to accelerate development without compromising the evidence regulators expect.
-
ArticleMass spectrometry workflows powering the future of biologics
Analysing complex biologics is one of drug discovery’s biggest challenges. At Genentech, Rachel Shi is developing MS workflows that deliver clearer answers, faster.
-
ArticleInside the search-and-develop model tackling 1,000 untreated skin diseases
With over 1,000 skin diseases lacking approved treatments, a search-and-develop model is changing how new therapies are sourced and developed. Chief Scientific Officer, Jacob Pontoppidan Thyssen, outlines the strategy behind it.
-
ArticleHow to select the optimal bispecific antibody format for therapeutic success
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
-
NewsHow to select the optimal bispecific antibody format for therapeutic success
Discover the key scientific, strategic and manufacturing factors that could decide whether your bsAb succeeds in the clinic or stalls in development.
-
ArticleChallenges in developing robust potency assays for ADCs
Developing robust potency assays for Antibody-Drug Conjugates (ADCs) is crucial for ensuring their clinical success, but designing assays that meet both technical and regulatory standards is challenging. Here, Abzena’s CSO Campbell Bunce explores the complexities of assay development and the importance of ensuring accuracy, consistency and regulatory alignment for ADCs ...
-
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
-
NewsTurning up the heat: simple temperature change makes versatile vaccine nanoparticles
University of Chicago researchers have developed a scalable nanoparticle platform that self-assembles with just a temperature change – enabling safe, solvent-free delivery of proteins and RNA for vaccines and therapies.
-
NewsAI-driven Alzheimer’s therapies show promise in early studies
Porosome Therapeutics has announced new advancements in Alzheimer’s treatment – presenting therapies that restore neuronal function, reduce Tau protein levels and reverse disease pathology in human brain organoids.
-
ArticleWhy most T-cell engagers fail - and how to fix it
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
-
ArticlePlasmids: Tackling Supply Chain and Manufacturing Challenges
Gene therapy’s progress depends on reliable supply chains and efficient manufacturing. In this episode, we explore the challenges and strategies involved in plasmid production - an essential component in advancing life-changing therapies.
-
ArticleDesigning antibodies to think before they bind
Standard antibody therapies bind their target and trigger a response. But what if the real breakthrough is designing antibodies that first recognise context before they act? This article looks at how bispecifics are becoming smarter, more selective and more precise.
-
ArticleThe future of CNS drug development: signs of real progress
New therapeutic approaches are emerging for CNS disorders – but can they overcome the toughest barriers in drug development? Find out what is driving progress and what still stands in the way.
-
NewsNew partnership targets CNS symptoms in ultra-rare diseases
Chiesi Group and Key2Brain have signed a global license agreement to develop two blood-brain barrier-crossing enzyme replacement therapies for alpha-mannosidosis and Krabbe disease – with the aim to help patients with limited treatment options.
-
NewsTurning AI into a biological design engine
DenovAI has unveiled a powerful AI-driven protein design platform capable of creating new, functional synthetic proteins from scratch - marking a big step forward for drug discovery.
-
ArticleRethinking antibody discovery in the age of automation
James Atwood, COO of Opentrons, shares how accessible lab automation is helping research teams tackle tighter budgets, faster timelines and complex discovery workflows.
-
ArticleHow GPCR-targeting therapies are advancing the fight against inflammatory disease
Discover how Domain Therapeutics is using its deep knowledge of GPCR biology to create novel therapeutics with the potential to combat inflammatory diseases such as atopic dermatitis, IBD and arthritis.
-
ArticleShifting the ADC focus from antibody to payload
While ADCs continue to attract attention in oncology, many developers remain focused on antibodies – overlooking the critical role of payload design. At Sygnature Discovery, Dr Joshua Greally is leading a shift in perspective, advocating for a payload-first approach through the company’s new platform, NewPath ADC. In this interview, he ...
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page